[HTML][HTML] Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
N Capasso, R Palladino, V Cerbone, AL Spiezia… - Journal of …, 2023 - Springer
Objective We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
N Capasso, R Palladino, V Cerbone… - Journal of …, 2023 - search.proquest.com
Objective We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.
N Capasso, R Palladino, V Cerbone… - Journal of …, 2023 - search.ebscohost.com
Objective: We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.
N Capasso, R Palladino, V Cerbone… - Journal of …, 2022 - europepmc.org
Objective We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
[HTML][HTML] Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
N Capasso, R Palladino, V Cerbone… - Journal of …, 2023 - ncbi.nlm.nih.gov
Objective We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
N Capasso, R Palladino, V Cerbone… - JOURNAL OF …, 2022 - iris.unina.it
We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20 monoclonal
antibody for the treatment of multiple sclerosis (MS)) on lymphocytes, neutrophils and …
antibody for the treatment of multiple sclerosis (MS)) on lymphocytes, neutrophils and …
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
N Capasso, R Palladino, V Cerbone… - JOURNAL OF …, 2022 - iris.uniroma1.it
We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20 monoclonal
antibody for the treatment of multiple sclerosis (MS)) on lymphocytes, neutrophils and …
antibody for the treatment of multiple sclerosis (MS)) on lymphocytes, neutrophils and …
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
N Capasso, R Palladino, V Cerbone… - Journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Objective We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
[PDF][PDF] Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3‑year observational study
N Capasso, R Palladino, V Cerbone, AL Spiezia… - inflammation, 2022 - iris.uniroma1.it
Objective We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.
N Capasso, R Palladino, V Cerbone… - Journal of …, 2022 - europepmc.org
Objective We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …